Company Overview - Karyopharm Therapeutics (KPTI) shares increased by 6.9% to $5.57, following a significant trading volume, despite a 48.4% loss over the past four weeks [1] Clinical Study Results - The company reported mixed results from the phase III SENTRY study, where a 60 mg dose of selinexor combined with Jakafi (ruxolitinib) showed a statistically significant 35% or more reduction in spleen volume (SVR35) but did not meet the second co-primary endpoint of absolute total symptom score (Abs-TSS) [2] Financial Expectations - Karyopharm is expected to report a quarterly loss of $1.35 per share, reflecting a year-over-year increase of 51.3%, with revenues projected at $34.6 million, up 15.3% from the previous year [3] Stock Performance Insights - Trends in earnings estimate revisions are correlated with near-term stock price movements, indicating that the stock's price may not sustain increases without changes in earnings estimates [4] Consensus and Future Outlook - The consensus EPS estimate for Karyopharm has remained unchanged over the last 30 days, suggesting that the recent stock price increase may need to be monitored for sustainability [5] Industry Context - Karyopharm Therapeutics is part of the Zacks Medical - Drugs industry, where Esperion Therapeutics (ESPR) also operates, having closed 3.3% higher at $2.85, but with a -17.1% return over the past month [6]

Core Insights - Karyopharm Therapeutics (KPTI) shares fell 18.3% following mixed results from a late-stage study of selinexor combined with Incyte's Jakafi for treating myelofibrosis [1][7] Study Results - The phase III SENTRY study involved 353 patients randomized to receive either selinexor plus Jakafi or placebo plus Jakafi [2] - The study met its first co-primary endpoint, showing a statistically significant 35% or more reduction in spleen volume (SVR35) in 50% of patients receiving the combination therapy, compared to 28% for Jakafi alone [3][5] - However, the second co-primary endpoint, absolute total symptom score (Abs-TSS), was not met, with similar symptom improvements observed in both treatment arms [3][6] Drug Background - Selinexor, marketed as Xpovio, is FDA-approved for multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma [4] - The drug is also available in the EU and UK under the name Nexpovio for multiple myeloma indications [4] Safety and Efficacy - The combination therapy demonstrated a manageable safety profile consistent with known effects of selinexor and Jakafi, with no new safety signals identified [11] - A promising overall survival trend was noted, with a hazard ratio of 0.43 suggesting potential survival advantages [9] Future Directions - Karyopharm plans to engage with the FDA to review the full SENTRY study dataset and discuss regulatory filing plans [15] - The company aims to present additional data from the SENTRY study at an upcoming medical conference [15] - Selinexor is also being evaluated in other oncology indications, and Karyopharm has another candidate, eltanexor, in mid-stage development for myelodysplastic neoplasms [16] Market Context - Karyopharm's stock has declined 20.8% over the past six months, compared to a 10.3% decline in the industry [6]

Core Viewpoint - Karyopharm Therapeutics Inc. reported mixed results from its Phase 3 SENTRY trial for myelofibrosis, leading to a decline in its stock price [1] Group 1: Trial Results - The SENTRY trial met its first co-primary endpoint, showing a significant improvement in spleen volume reduction of 35% or more for patients treated with selinexor plus ruxolitinib [2] - The trial indicated a promising overall survival signal, with a greater than 50% reduction in the risk of death compared to ruxolitinib alone [3] - 50% of patients on the combination achieved SVR35 at week 24, compared to 28% for those on ruxolitinib alone [4] Group 2: Symptom Scores and Secondary Endpoints - Patients on the combination treatment reported a 9.89-point improvement in symptoms, while those on ruxolitinib alone reported a 10.86-point improvement [5] - The trial did not meet its second co-primary endpoint of absolute total symptom score, and no meaningful differences were observed in secondary endpoints such as progression-free survival and hemoglobin stabilization [6] Group 3: Future Plans and Financials - Karyopharm plans to further evaluate trial endpoints and share additional data at an upcoming medical meeting, with a manuscript submission expected to a peer-reviewed journal [7] - The company announced a private placement of approximately $30 million, with potential additional gross proceeds of about $44 million if accompanying warrants are exercised [8] Group 4: Analyst Outlook - Analysts maintain a bullish outlook on Karyopharm, with the stock carrying a Buy Rating and an average price target of $42.17 [9] - Karyopharm shares were down 17.43% at $6.04 at the time of publication [9]

Karyopharm Therapeutics Conference Call Summary Company Overview - **Company**: Karyopharm Therapeutics (NasdaqGS: KPTI) - **Focus**: Development of treatments for myelofibrosis, particularly the combination of selinexor and ruxolitinib Key Industry Insights - **Industry**: Myelofibrosis treatment - **Current Landscape**: Myelofibrosis remains a disease with significant unmet needs, with current therapies providing modest spleen responses and limited disease modification. JAK inhibitors are the only approved class of therapies, highlighting the need for new treatment options that can improve patient outcomes, especially overall survival [1][2][94] Core Findings from the SENTRI Trial - **Trial Design**: Phase III SENTRI trial evaluated selinexor in combination with ruxolitinib in JAK inhibitor-naive myelofibrosis patients. A total of 353 patients were randomized in a 2-to-1 ratio [8][9] - **Primary Endpoints**: The trial had two co-primary endpoints: spleen volume reduction (SVR35) and absolute total symptom score (TSS) at week 24 [9] - **Efficacy Results**: - **SVR35 Rates**: The combination therapy achieved SVR35 rates of 50% compared to 28% for ruxolitinib alone, with a p-value of less than 0.0001, indicating a highly significant improvement [10] - **Overall Survival**: The combination demonstrated a greater than 50% reduction in the risk of death compared to ruxolitinib alone, with overall survival events at 4.7% for the combination versus 10.2% for ruxolitinib, corresponding to a hazard ratio of 0.43 and a nominal p-value of 0.0222 [11] - **Variant Allele Frequency (VAF)**: VAF reductions greater than or equal to 20% at week 24 were observed in 32% of combination-treated patients versus 24% of ruxolitinib-treated patients, suggesting potential disease modification [12] Safety Profile - **Adverse Events**: The safety profile was consistent with known profiles of selinexor and ruxolitinib, with no new safety signals identified. The most common treatment-emergent adverse events included thrombocytopenia (59%), anemia (57%), and nausea (57%) [14][15] - **Grade 3+ Adverse Events**: Observed in 14.5% of patients treated with the combination versus 8.6% for ruxolitinib alone, indicating a manageable safety profile [80] Implications for Treatment - **Clinical Significance**: The results suggest that the combination of selinexor and ruxolitinib could be a meaningful new treatment option for myelofibrosis, with rapid and sustained improvements in spleen volume and a promising overall survival signal [16][26] - **Future Directions**: Karyopharm plans to engage with the FDA regarding the SENTRI data and potential sNDA filing, as well as present findings at upcoming medical meetings [26] Additional Considerations - **Patient Population**: The combination therapy may be particularly beneficial for patients with severe splenomegaly and high symptom burden, although the exact patient profile for optimal use remains to be fully defined [75] - **NCCN Guidelines**: The potential for inclusion in NCCN guidelines could facilitate broader adoption of the combination therapy in clinical practice [50][49] Conclusion - The SENTRI trial results represent a significant advancement for Karyopharm and the myelofibrosis community, indicating the potential for improved treatment outcomes and addressing unmet needs in this patient population [94]

Core Insights - Karyopharm Therapeutics Inc. reported positive topline results from its Phase 3 SENTRY trial of selinexor in combination with ruxolitinib for frontline myelofibrosis, leading to a more than 15% increase in share price during pre-market trading [1] Group 1: Trial Results - The trial met its first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction of at least 35% (SVR35) in patients treated with the combination compared to ruxolitinib alone [1] - At week 24, 50% of patients receiving the selinexor combination achieved SVR35, compared to 28% in the ruxolitinib-only group [2] - The combination treatment showed earlier and sustained responses, with 49% achieving SVR35 at week 12 versus 20% for ruxolitinib alone, and 47% at week 36 compared to 23% [2] Group 2: Symptom Improvement - Symptom improvement was comparable between the two groups, with a 9.89-point reduction in total symptom score for the combination group versus a 10.86-point reduction for the ruxolitinib-only group at week 24 [3] Group 3: Overall Survival and Future Plans - The combination demonstrated a promising overall survival signal with a hazard ratio of 0.43, and the company will continue to follow survival data to maturity [4] - Karyopharm plans to meet with the U.S. Food and Drug Administration to discuss the trial data and a potential supplemental new drug application filing [4]

Core Insights - The partnership between Medidata and The Menarini Group has evolved to incorporate AI technology, specifically Medidata AI Study Build, to enhance the efficiency of clinical trials in oncology [1][2][3] - Stemline Therapeutics, a subsidiary of Menarini, aims to accelerate the initiation of clinical trials for oncology treatments, significantly reducing the time from protocol finalization to trial startup [2][3] Group 1: Partnership Expansion - Medidata and Menarini have expanded their collaboration after 14 years, focusing on integrating AI into clinical workflows to improve oncology research [1][3] - The use of Medidata AI Study Build technology will allow Stemline to leverage a large clinical data set of over 38,000 trials, automating configurations and expediting trial processes [2][3] Group 2: Impact on Oncology Research - The integration of AI is expected to modernize the trial lifecycle, enhancing the speed and quality of data delivery for oncology research [2][6] - Menarini's CEO emphasized the importance of innovation and the role of Medidata AI in streamlining workflows to bring new treatment options to patients more quickly and safely [2][3] Group 3: Company Background - The Menarini Group is a significant player in the pharmaceutical and diagnostics industry, with a turnover of $5 billion and a focus on high unmet medical needs across various therapeutic areas [7] - Stemline Therapeutics specializes in oncology treatments, with products like elacestrant and tagraxofusp-erzs, and is actively conducting multiple clinical studies to expand its treatment offerings [8]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $44 million, an increase of 13.4% compared to $38.8 million in Q3 2024 [26] - U.S. net product revenue for XPOVIO grew 8.5% year over year to $32 million [26] - License and other revenue was $12 million in Q3 2025, up nearly 30% from Q3 2024 [27] - Gross to net provisions for XPOVIO were 27% in Q3 2025, consistent with Q2 2025 and down from 31% in Q3 2024 [26] - The net loss was $33.1 million, or $3.82 per share on a GAAP basis, with more than half of this loss driven by non-operational items [29] Business Line Data and Key Metrics Changes - XPOVIO net product revenue in Q3 2025 was $32 million, reflecting continued strength in the multi-biomodal market [20] - The company is focused on advancing late-stage clinical programs, particularly SENTRY and ECO42, which are expected to be transformative [6] Market Data and Key Metrics Changes - The company sees a significant opportunity in the myofibrosis market, with approximately 20,000 patients living with the condition in the U.S. [23] - There are about 4,000 newly diagnosed patients each year in the U.S. with intermediate to high-risk myofibrosis who could benefit from the combination therapy [23] Company Strategy and Development Direction - The company aims to redefine the standard of care for myofibrosis through the combination of selinexor and ruxolitinib [4] - The strategy includes maintaining financial discipline while driving growth across the XPOVIO franchise and advancing clinical programs [6] - The company is preparing for a potentially transformative commercial launch in myofibrosis, driven by high unmet needs and lack of innovation in the market [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming top-line data from the SENTRY trial, expected in March 2026, which could reshape treatment paradigms [4] - The company has secured approximately $100 million in financial flexibility, extending its cash runway into Q2 2026 [5] - Management emphasized the importance of executing with clarity and purpose to deliver innovative cancer therapies [7] Other Important Information - The company has completed enrollment in the phase three SENTRY trial, marking a pivotal moment for its myofibrosis program [4] - The company has a strong commercial foundation and existing capabilities that will support a rapid launch if the trial data is positive [25] Q&A Session Summary Question: Can you walk through what we should see for MF data in March 2026? - Management anticipates providing top-line details, including primary endpoints of SVR35 and absolute TSS, with potential secondary endpoints [34][35] Question: What is the size of the sales force for myofibrosis? - Minimal additions to the commercial structure are expected due to strong overlap with existing capabilities [36] Question: Are there any milestones associated with recent financial restructuring? - No specific triggers related to positive data were mentioned, but positive data could significantly enhance value [37] Question: Can you discuss the commercial potential launch in myofibrosis? - The company is leveraging learnings from multiple myeloma to optimize trial design and patient outcomes [48][49]

Financing and Capital Structure - Karyopharm Therapeutics Inc. announced comprehensive financing and capital structure transactions expected to provide $100 million of financial flexibility, extending the cash runway into Q2 2026 [1] - The company is exploring potential financing and strategic alternatives to enhance liquidity and maximize value, with Centerview Partners acting as the financial advisor [2] - A private placement of approximately $8.75 million will involve the sale of 1.49 million shares and warrants to purchase 1.32 million shares at an exercise price of $6.64 per share [2] Revenue Expectations - The company expects total revenue, including license and royalty revenue from partners, to be between $42 million and $44 million, with U.S. XPOVIO net product revenue anticipated to be approximately $32 million for Q3 2025 [3] Clinical Trials - Enrollment continues in the Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer, with topline data expected in mid-2026 [4] - The company completed enrollment in the Phase 3 SENTRY trial, which evaluates selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients, with topline data anticipated in March 2026 [4][5] Stock Performance - Karyopharm stock is down 12.74% at $5.03 at the time of publication [5]

Karyopharm Therapeutics (KPTI) Conference Summary Company Overview - Karyopharm Therapeutics is an innovation-driven commercial stage oncology company focusing on myelofibrosis and endometrial cancer treatments [3][4] Key Points on Myelofibrosis - The company is conducting two transformative Phase 3 studies: one for myelofibrosis and another for endometrial cancer, with top-line data expected by the end of 2025 or early 2026 [2][4] - The potential peak opportunity for myelofibrosis treatment is projected to exceed $1 billion [5] - The ongoing Phase 3 program targets JAK naive patients, with a focus on the efficacy of selinexor in combination with ruxolitinib [5][6] - Selinexor has shown promising results in heavily pretreated patients, demonstrating significant spleen volume reduction and symptom improvement [6][16] - The combination therapy has achieved a 79% SVR 35 rate compared to the 30-35% rate seen with ruxolitinib alone [16][28] - The durability of response is notable, with a 100% probability of maintaining spleen volume reduction among patients achieving SVR 35 [18] - The company emphasizes the importance of modifying the underlying disease and improving patient outcomes through innovative treatment approaches [34] Key Points on Endometrial Cancer - Karyopharm is leveraging the p53 wild type biomarker in endometrial cancer, which is present in approximately 50% of patients [38][39] - Selinexor has demonstrated a median progression-free survival (PFS) of 28.4 months in p53 wild type patients, significantly outperforming placebo [40] - The ongoing Phase 3 trial for endometrial cancer will evaluate selinexor as a monotherapy in a maintenance setting, with a planned enrollment of 276 patients [41] Additional Insights - The company has established commercialization capabilities to rapidly launch treatments upon receiving positive data [9][10] - The focus on innovative therapies aims to transform treatment standards in both myelofibrosis and endometrial cancer, enhancing patient outcomes [44] - The management team expresses confidence in the potential of selinexor to address unmet needs in oncology, particularly in challenging patient populations [11][12] Conclusion - Karyopharm Therapeutics is positioned for significant advancements in oncology with its innovative treatments for myelofibrosis and endometrial cancer, backed by promising clinical data and a strong commercialization strategy [44]

Financial Performance - Karyopharm Therapeutics reported quarterly losses of $2.77 per share, which was better than the analyst consensus estimate of losses of $4.16 per share [1] - The company reported quarterly sales of $30.02 million, missing the analyst consensus estimate of $35.24 million [1] Clinical Trial Update - The Phase 3 SENTRY trial in patients with JAKi-naïve myelofibrosis has passed its pre-specified futility analysis and continues as planned without modifications [2] - New data in hard-to-treat myelofibrosis patients showed spleen volume reduction, symptom improvement, hemoglobin stabilization, and evidence of disease modification with selinexor monotherapy [2] Sales Guidance and Market Reaction - Karyopharm affirmed FY2025 sales guidance of $140.00 million to $155.00 million, compared to market estimates of $149.32 million [3] - Following the earnings announcement, Karyopharm shares fell 15.6% to trade at $5.17 [3] Analyst Ratings and Price Targets - Baird analyst Michael Ulz maintained an Outperform rating and lowered the price target from $54 to $42 [8] - Barclays analyst Peter Lawson maintained an Overweight rating and raised the price target from $5 to $10 [8] - RBC Capital analyst Brian Abrahams maintained an Outperform rating and lowered the price target from $34 to $33 [8]